We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+11.72%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.39B
AUM Growth
-$174M
Cap. Flow
-$28.5M
Cap. Flow %
-0.84%
Top 10 Hldgs %
46.4%
Holding
115
New
19
Increased
20
Reduced
20
Closed
16

Top Buys

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$127M
2
ACLX
Arcellx
ACLX
+$37.7M
3
SNY icon
Sanofi
SNY
+$37.4M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$37M
5
APLS
Apellis Pharmaceuticals
APLS
+$32M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$109M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$50.4M
3
VRNA
Verona Pharma
VRNA
+$46.4M
4
ALBO
Albireo Pharma Inc
ALBO
+$38M
5
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$31.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.49%
2 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VERU icon
76
Veru
VERU
$35.5M
$4.99M 0.15%
429,821
-355,980
-45% -$14.4M
LABP
77
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$4.43M 0.13%
1,486,992
– –
OMIC
78
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$3.97M 0.12%
109,409
– –
XFOR icon
79
X4 Pharmaceuticals
XFOR
$377M
$3.95M 0.12%
+151,515
New +$4.44M
SLGC
80
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$3.83M 0.11%
1,500,000
– –
NBTX
81
Nanobiotix
NBTX
$1.92B
$3.74M 0.11%
1,059,800
– –
NVNO
82
enVVeno Medical
NVNO
$6.94M
$3.66M 0.11%
22,332
– –
VIR icon
83
Vir Biotechnology
VIR
$1.46B
$3.31M 0.1%
+142,194
New +$3.64M
HRMY icon
84
Harmony Biosciences
HRMY
$2.08B
$3.27M 0.1%
100,000
-311,804
-76% -$14.2M
ADCT icon
85
ADC Therapeutics
ADCT
$140M
$2.92M 0.09%
+1,495,805
New +$5.52M
CELL
86
DELISTED
PhenomeX Inc. Common Stock
CELL
$2.91M 0.09%
+2,506,442
New +$4.58M
KRON
87
DELISTED
Kronos Bio
KRON
$2.56M 0.08%
1,752,745
– –
CYPH
88
Cypherpunk Technologies Inc
CYPH
$64M
$2.29M 0.07%
672,650
– –
TVTX icon
89
Travere Therapeutics
TVTX
$5.17B
$2.04M 0.06%
90,748
– –
QTRX icon
90
Quanterix
QTRX
$159M
$1.47M 0.04%
+130,000
New +$1.66M
DRIO icon
91
DarioHealth
DRIO
$51.9M
$1.29M 0.04%
15,693
-700
-4% -$68.7K
CLOV icon
92
Clover Health Investments
CLOV
$2.23B
$1.27M 0.04%
1,500,000
– –
ATNX
93
DELISTED
Athenex, Inc. Common Stock
ATNX
$1.03M 0.03%
776,623
– –
TARA icon
94
Protara Therapeutics
TARA
$214M
$908K 0.03%
290,051
– –
PEAR
95
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
$230K 0.01%
900,548
– –
MOTS
96
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$87.6K ﹤0.01%
6,002
– –
EQRXW
97
DELISTED
EQRx, Inc. Warrant
EQRXW
$43.1K ﹤0.01%
250,000
– –
CMAXW
98
DELISTED
CareMax, Inc. Warrant
CMAXW
$28.9K ﹤0.01%
60,000
– –
SRZNW icon
99
Surrozen Inc Warrant
SRZNW
$36.6K
$16.7K ﹤0.01%
166,666
– –
ABOS icon
100
Acumen Pharmaceuticals
ABOS
$152M
– –
-347,450
Closed -$1.88M
1 2 3
4
5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2023 Portfolio in Review

As of Q1 2023, Perceptive Advisors held 115 positions worth $3.39B, down 4.9% from $3.56B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors's Q1 2023 filing shows 19 new, 20 increased, 20 reduced and 16 closed positions. Its largest new stake was Reata Pharmaceuticals, Inc. Class A Common Stock: 2,169,276 shares worth $197M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $109M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Financials.

  • Perceptive Advisors's largest Q1 2023 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 2,169,276 shares worth $197M.
  • Perceptive Advisors added most to Arcellx in Q1 2023, an estimated $37.7M increase.
  • Perceptive Advisors's biggest Q1 2023 reduction was Sarepta Therapeutics, cutting an estimated $50.4M.
  • Perceptive Advisors fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023, selling an estimated $109M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $3.39B portfolio in Q1 2023.
  • Perceptive Advisors opened 19 new positions and closed 16 in Q1 2023.
  • Perceptive Advisors's portfolio value fell 4.9% quarter-over-quarter to $3.39B.

Based on Perceptive Advisors's 13F filing for Q1 2023, filed 15 May 2023.